Characterization of a case of virological failure after switch to long-acting cabotegravir and rilpivirine-Reference-Cited by-同舟云学术

Characterization of a case of virological failure after switch to long-acting cabotegravir and rilpivirine

Published:2024-06-21 Issue:8 Volume:79 Page:2074-2076
ISSN:0305-7453
Container-title:Journal of Antimicrobial Chemotherapy
language:en
Short-container-title:

Author:

Mazzitelli Maria¹^ORCID,Avolio Antonio²,Carandina Riccardo³,Parisi Saverio⁴,Wensing Annemarie⁵,Cattelan Annamaria¹

Affiliation:

1. Infectious and Tropical Diseases Unit, Padua University Hospital , Padua , Italy

2. Laboratory and Clinical Pharmacology and Pharmacogenetics, Department of Medical Sciences, University of Turin , Turin , Italy

3. Radiodiagnostic Unit, University Hospital of Padua , Padua , Italy

4. Department of Molecular Medicine, Padua University Hospital , 35128 Padua , Italy

5. Translational Virology, Department of Medical Microbiology, University Medical Center Utrecht , Utrecht , The Netherlands

Publisher

Oxford University Press (OUP)

Link

https://academic.oup.com/jac/article-pdf/79/8/2074/58689022/dkae187.pdf

Reference11 articles.

1. Major revision version 12.0 of the European AIDS Clinical Society Guidelines 2023;Ambrosioni;HIV Med,2023

2. Expanded multivariable models to assist patient selection for long-acting cabotegravir + rilpivirine treatment: clinical utility of a combination of patient, drug concentration, and viral factors associated with virologic failure;Orkin;Clin Infect Dis,2023

3. Impact of integrase sequences from HIV-1 subtypes A6/A1 on the in vitro potency of cabotegravir or rilpivirine;Jeffrey;Antimicrob Agents Chemother,2022

4. Real-world trough concentrations and effectiveness of long-acting cabotegravir and rilpivirine: a multicenter prospective observational study in Switzerland;Thouielle;Lancet Reg Health,2024

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Therapeutic failure reported with HIV long‐acting injectables: An analysis of the FDA Adverse Event Reporting System from 2021 to 2024;HIV Medicine;2024-09-05